Founding of a specialist cancer hospital
Established on March 1, 1931, the hospital began a cancer care tradition now spanning more than nine decades.
Affiliated with Fudan UniversityShanghai Cancer Center
Third nationally for oncology reputation, and birthplace of the Fudan classification of breast cancer.
Founded in 1931, Fudan University Shanghai Cancer Center ranked third in oncology and second in pathology in the 2023 Fudan National Specialty Reputation Rankings. With seven national key clinical specialties, it integrates pathological diagnosis, multidisciplinary treatment and classification research. The Fudan classification of triple-negative breast cancer and individualized treatment of pancreatic neuroendocrine tumors exemplify its connection between clinical care and research.
Shanghai, China
More than nine decades of cancer expertise, contributing Chinese advances in precise classification.
Founded in 1931, with pathology established in 1949, the hospital brings diagnostic foundations, surgery, drug treatment and radiotherapy into one specialist cancer system. Its breast, pancreatic and other teams use molecular classification and clinical research to improve understanding of disease and treatment strategies.
National reputation in oncology and pathology, national key clinical specialties and original classification research support expertise from diagnosis through combined treatment.
National specialty reputation and key specialties
2023 Fudan National Specialty Reputation Rankings · Published in November 2024
OncologyNo. 3
2023 national specialty reputation
PathologyNo. 2
2023 national specialty reputation
National key clinical specialties7
The hospital's current introduction · Checked in September 2026
Oncology and pathology are the ranking's original specialty categories, rather than outcome rankings for individual cancers.
Seven national key clinical specialties
The hospital's current introduction lists seven national key clinical specialties, alongside Shanghai key laboratories for breast tumors, pancreatic tumors, radiation oncology and other fields.
Connecting pathological diagnosis and cancer treatment
Established in 1949, pathology is a national key clinical specialty. The hospital also operates dedicated multidisciplinary outpatient services, wards and disease-specific treatment centers.
The Fudan classification of triple-negative breast cancer
Shao Zhimin and Jiang Yizhou's team published multiomics research in 2019 identifying four subtypes, followed by the FUTURE trial and development of an immunohistochemistry-based testing method.
Establishment of pathology
This laid the foundation for tumor pathology diagnosis. The department later became a national key clinical specialty and the host institution for the Shanghai Clinical Pathology Quality Control Center.
Establishment of pancreatic surgery
Yu Xianjun founded the pancreatic surgery department, developing individualized combined treatment centered on surgery.
Introducing the Fudan classification of triple-negative breast cancer
The research divided triple-negative breast cancer into four molecularly distinct subtypes and was published in Cancer Cell.
Leading specialties,
built on medical achievements.
Explore Shanghai Cancer Center's contributions in each field, from specialty standing to notable achievements, and the conditions this expertise supports.
The Fudan classification of triple-negative breast cancer
Original research in 2019 · Published in Cancer Cell
Breast surgery connects molecular breast cancer profiling with treatment research. Shao Zhimin, Jiang Yizhou and colleagues proposed four triple-negative subtypes, then advanced more accessible testing methods and subtype-driven clinical trials.
Establishing four subtypes of triple-negative breast cancer
2019 · Multiomics and molecular classificationUsing genomic, transcriptomic and clinical patient data, the team identified luminal androgen receptor, immunomodulatory, basal-like immune-suppressed and mesenchymal subtypes.
The subtype-driven FUTURE clinical trial
2020 · Published in Cell ResearchFor triple-negative breast cancer progressing after multiple lines of treatment, the team conducted an umbrella trial using subtype and molecular testing to explore matched treatments for different subtypes.
Classification incorporated into Chinese treatment guidelines
The immunohistochemical classification method entered the Chinese Anti-Cancer Association's Breast Cancer Diagnosis and Treatment Guidelines and Standards in 2021, bringing research into clinical testing.
Breast surgery and research platforms
The breast surgery department and associated research platforms were established in 2000. Their current scope includes surgery, systemic therapy and clinical research.
What conditions can this expertise help address?
Newly diagnosed breast cancer requires a plan based on pathology and receptor results. Triple-negative or recurrent metastatic disease also requires review of subtype, previous medications and changes in lesions when discussing surgery, systemic therapy or research assessment.
National training base for pancreatic tumor specialists
Hospital specialty credentials · Checked in September 2026
The pancreatic surgery and pancreatic cancer multidisciplinary treatment department was established in 2010. Its main research areas are surgical techniques, tumor staging and individualized combined treatment. It is also the institution of the chair of the Chinese Anti-Cancer Association's Pancreatic Cancer Committee.
An innovative papillary pancreaticojejunostomy technique
A contribution to pancreatic surgical techniqueThe department developed papillary pancreaticojejunostomy and dedicated pancreatic surgical instruments, improving digestive tract reconstruction after resection and surgical procedures.
Individualized strategies for pancreatic neuroendocrine tumors
2024 · Inaugural Shanghai Municipal Hospital Clinical Innovation AwardYu Xianjun's team studied surgical approaches, lymph node management and recurrence prediction, proposing modified staging and risk models to establish individualized treatment strategies.
Surgery and combined treatment within one department
The pancreatic surgery/pancreatic cancer multidisciplinary treatment department brings together collaboration in surgery, endoscopy, interventional procedures and drug treatment.
Guidelines and multicenter research
The team led the Chinese Anti-Cancer Association Guidelines for the Diagnosis and Treatment of Neuroendocrine Tumors (2022) and an English-language expert consensus, drawing on domestic multicenter data.
What conditions can this expertise help address?
Pancreatic cancer and pancreatic neuroendocrine tumors require separate assessment. The team considers resectability, whether some pancreatic function can be preserved, systemic treatment sequencing, and postoperative recurrence risk and follow-up.
Meet the specialists
through their achievements.
Discover the specialists' contributions and the conditions and treatments they focus on.
Showing 2 representative specialists
Shao Zhimin
Breast surgery
Chief physician
Leading researcher behind the Fudan classification of triple-negative breast cancer
Ask about this doctorDefining four triple-negative breast cancer subtypes and advancing subtype-driven precision treatment research
Shao Zhimin, Jiang Yizhou and colleagues established a classification system for triple-negative breast cancer, translating multiomics findings into testing methods and clinical trials.
Jointly proposing the Fudan classification
In 2019, he published research in Cancer Cell with Jiang Yizhou and colleagues, establishing four molecular subtypes of triple-negative breast cancer and a corresponding research framework.
Bringing classification into clinical research and care standards
His team conducted the FUTURE trial and developed an immunohistochemical classification method, which entered Chinese breast cancer treatment guidelines in 2021.
Conditions and treatment expertise
- Newly diagnosed breast cancer and surgery
- Assessment of surgery and combined treatment for breast cancer, with treatment planned according to pathology, stage and molecular type.
- Triple-negative and recurrent metastatic breast cancer
- Discussion of systemic therapy and clinical research suitability in light of triple-negative subtype, recurrence and metastasis risks, and previous treatment.
Yu Xianjun
Pancreatic surgery
Chief physician · Professor
Recipient of the National Science Fund for Distinguished Young Scholars · Leading expert in a pancreatic tumor clinical innovation award project
Ask about this doctorFounding pancreatic surgery and leading an award-winning pancreatic tumor clinical innovation project
Yu Xianjun's work spans pancreatic tumor surgery, combined treatment and translational research, emphasizing differences in tumor biology, surgical extent and preservation of pancreatic function.
Founding a pancreatic surgery and combined treatment team
He established Fudan Cancer Center's pancreatic surgery department in 2010, advancing integrated development of surgery and combined treatment, and later received support from the National Science Fund for Distinguished Young Scholars.
Clinical Innovation Award for individualized treatment strategies
He led the development and application of new individualized strategies for pancreatic neuroendocrine tumors, receiving the inaugural Shanghai Municipal Hospital Clinical Innovation Award in 2024 for work on surgical selection, lymph node risks and recurrence prediction.
Conditions and treatment expertise
- Pancreatic cancer and complex pancreatic tumors
- Surgery and combined treatment for pancreatic tumors, including assessment of resectability and coordination between treatment stages.
- Pancreatic neuroendocrine tumors
- Assessment of surgical approach, pancreatic function preservation and postoperative management according to tumor grade, extent and biological characteristics.
These profiles describe professional expertise and notable experience. The doctor, campus and appointment time are confirmed when arranging care.
Want to learn about Shanghai Cancer Center?
Contact us directly.
Tell eastmedgo about the specialty, doctor or care question that matters to you, through WhatsApp or email.
Initial service inquiries are free. Medical assessments and treatment recommendations are provided by the receiving hospital and doctors.
Related reading
Medical guides related to this hospital’s specialties.
Breast surgery
Breast-conserving surgery in Shanghai: plan the radiotherapy path first
A guide to lumpectomy decisions, surgical margins and radiotherapy coordination when considering breast cancer surgery in Shanghai and follow-up at home.
Read articleWhy treatment may come before surgery for early triple-negative breast cancer
A Shanghai review of neoadjuvant treatment for nonmetastatic TNBC: confirm subtype, stage, expected benefit, risks and the surgical plan.
Read article
